Loading organizations...
§ Venture Capital · Jiangshu, Jiangsu, China
USD investment vehicle specializing in private equity and venture capital for bio-tech companies, with 20+ years experience.
King Star Capital is a USD investment vehicle established by Kington Capital, specializing in private equity and venture capital investments with a primary focus on innovative bio-tech companies. Its core team possesses over two decades of experience in financing technology companies and various industries, leveraging this deep expertise to identify and support promising ventures. The firm actively invests across the biotechnology sector, notably participating as a major investor in a previous funding round for Duality Biologics, a company that subsequently completed a $90 million Series B financing round. King Star Capital strategically targets early-stage and growth-stage companies developing disruptive technologies and novel solutions within the life sciences and healthcare domains, aiming to foster significant advancements. Established in 2017, the organization's founder information is not publicly available.
King Star Capital has 3 tracked investments across 3 companies. The latest tracked deal is $85.0M Series B in Gracell Biotechnologies in February 2019.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 25, 2019 | Gracell Biotechnologies | $85.0M Series B | Temasek | Chengdu Miaoji, Kington Capital, Lilly Asia Ventures |
| May 9, 2018 | CStone Pharmaceuticals | $259.2M Series B | GIC | 3W Partners, 6 Dimensions Capital, ARCH Venture Partners, AVICT Global, Boyu Capital, CPE, Hillhouse Capital, Hongshan Capital Group (Sequoia Capital China), Taikang, Terra Magnum Capital Partners, WuXi Healthcare Ventures, Yunfeng Capital |
| Mar 1, 2018 | Adagene | $50.0M Series C | Hongshan Capital Group (Sequoia Capital China) | Base Partners, DST Global, Carmen Chang, Hans Tung, Paradigm, Sequoia Capital China, AVIC Trust, Gopher Asset Management, NEW World TMT |